Table of contents

Key facts

Active substance
  • pembrolizumab
  • Vibostolimab
Therapeutic area
Decision number
PIP number
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of all conditions included in the category of malignant neoplasms (except nervous system neoplasms, haematopoietic and lymphoid tissue neoplasms and melanoma)
  • Treatment of malignant neoplasms of the central nervous system
Route(s) of administration
Intravenous use
Contact for public enquiries
Merck, Sharp & Dohme (Europe) Inc.

Tel. +33 180464738
E-mail: pip.information@merck.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications


How useful was this page?

Add your rating